SAN CARLOS, Calif. & SEATTLE, Aug. 18, 2026
BeOne Medicines Ltd., together with the BeOne Care Foundation and The Max Foundation, has renewed its partnership through 2028 to expand access to BRUKINSA® (zanubrutinib) for people living with chronic lymphocytic leukemia (CLL) in low- and middle-income countries. The renewed program is expected to support approximately 1,000 patients cumulatively by 2028, building on a collaboration that has already provided treatment access to more than 300 patients across Armenia, Ethiopia and Nepal. The initiative highlights a broader effort to reduce barriers to innovative cancer medicines in underserved healthcare settings, combining BeOne Medicines’ medicine donation, the BeOne Care Foundation’s financial support and The Max Foundation’s experience in implementing oncology access programs.
Partnership Expands Global Oncology Access
The renewed collaboration extends an access model launched in 2023, with the organizations continuing to support eligible patients in Armenia, Ethiopia and Nepal while assessing opportunities to expand into additional low- and middle-income countries. Potential expansion markets include Côte d’Ivoire, Malawi, Mongolia, Mozambique, Togo and Zambia, subject to operational readiness and evolving healthcare access priorities. The program is designed not only to provide BRUKINSA treatment, but also to strengthen the infrastructure required for continuity of cancer care. Under the agreement, the BeOne Care Foundation will provide a $1 million grant over the next two years to support patient care, physician engagement and operational activities, while BeOne Medicines will provide donated BRUKINSA. The Max Foundation will contribute its expertise in delivering structured oncology access programs and working with local healthcare providers.
BRUKINSA Access Builds on 300+ Patients Treated
A key development for the renewed partnership is the expansion of the program’s projected reach to approximately 1,000 patients through 2028. The original collaboration has already exceeded expectations, providing access to BRUKINSA to more than 300 people with CLL, approximately 150 more patients than initially planned. The continuation of the program is intended to create a more sustainable pathway for patients who may otherwise face significant limitations in accessing innovative oncology therapies. Importantly, patients enrolled through the program are expected to continue receiving treatment beyond the partnership term for as long as medically needed, supporting continuity of care rather than limiting assistance to the duration of the collaboration. The initiative therefore represents not simply a medicine donation effort, but a broader patient-access and healthcare-support model aimed at improving treatment availability in regions where innovative cancer medicines can remain difficult to obtain.
Advertisement
CLL Treatment Access Remains a Major Need
Chronic lymphocytic leukemia, the most common leukemia in adults, represents approximately one-third of new adult leukemia cases globally. Although treatment options have advanced substantially, access to newer targeted therapies remains uneven across healthcare systems, particularly in low- and middle-income countries. BRUKINSA (zanubrutinib) is a targeted cancer therapy developed by BeOne Medicines and is being made available through the renewed access initiative to address this treatment gap. The partnership brings together three complementary capabilities: BeOne Medicines contributes the medicine and oncology expertise, BeOne Care Foundation provides financial support, and The Max Foundation delivers program implementation and local healthcare coordination. With the renewed agreement extending through 2028, the organizations aim to broaden access, potentially reach additional countries and establish a scalable framework for delivering innovative cancer treatment to underserved populations.
Source:BeOne Medicines press relese
